keyword
MENU ▼
Read by QxMD icon Read
search

third-line

keyword
https://www.readbyqxmd.com/read/29777823/updated-efficacy-analysis-including-secondary-population-results-for-oak-a-randomized-phase-iii-study-of-atezolizumab-vs-docetaxel-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer
#1
L Fehrenbacher, J von Pawel, K Park, A Rittmeyer, D R Gandara, S Ponce Aix, J-Y Han, S M Gadgeel, T Hida, D L Cortinovis, M Cobo, D M Kowalski, F De Marinis, M Gandhi, B Danner, C Matheny, M Kowanetz, P He, F Felizzi, H Patel, A Sandler, M Ballinger, F Barlesi
INTRODUCTION: The efficacy and safety of atezolizumab vs docetaxel as second- or third-line treatment in patients with advanced non-small cell lung cancer in the primary (n=850; ITT850) and secondary (n=1225; ITT1225) efficacy populations of the randomized phase III OAK study at an updated data cutoff were assessed. METHODS: Patients received atezolizumab 1200mg or docetaxel 75mg/m2 intravenously every 3 weeks until loss of clinical benefit or disease progression, respectively...
May 16, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29774152/acquisition-of-double-mutation-in-gyra-caused-high-resistance-to-sitafloxacin-in-helicobacter-pylori-after-unsuccessful-eradication-with-sitafloxacin-containing-regimens
#2
Hideki Mori, Hidekazu Suzuki, Juntaro Matsuzaki, Tatsuhiro Masaoka, Takanori Kanai
Background and aim: Although sitafloxacin (STFX)-containing regimens are effective rescue treatments for Helicobacter pylori infection, prevalence of fluoroquinolone resistance in H. pylori has increased rapidly worldwide. The change in resistance levels and gyrA mutations, a major cause of fluoroquinolone resistance, after unsuccessful STFX-containing treatment has not been investigated. Methods: We conducted a retrospective, non-randomized study to compare the minimum inhibitory concentrations (MICs) of STFX and the location of gyrA mutations in H...
April 2018: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/29772036/chronic-urticaria-following-practice-guidelines
#3
E P Westby, C Lynde, G Sussman
Histamine is a key inflammatory player in the pathogenesis of urticaria, a mast-cell-driven disease characterized clinically by the development of wheals, angioedema, or both. Changes to the management of chronic spontaneous urticaria have recently been adopted due to increasing literature surrounding the efficacy and safety of up-dosing modern second-generation H1 -antihistamines and the use of omalizamub, a biologic agent, as a third-line treatment. Given the prevalence of chronic urticaria and its impact on quality of life, this editorial aims to provide a summary of the proposed updated guidelines for the management of chronic urticaria as agreed upon at the 5th Consensus Conference on the Update and Revision of the EAACI/GA2 LEN/EDF/WAO Guideline for Urticaria in Berlin in December 2016...
May 2018: Skin Therapy Letter
https://www.readbyqxmd.com/read/29770798/combined-treatment-with-apatinib-and-docetaxel-in-a549-xenograft-mice-and-its-cellular-pharmacokinetic-basis
#4
Si-Qi Feng, Guang-Ji Wang, Jing-Wei Zhang, Yuan Xie, Run-Bin Sun, Fei Fei, Jing-Qiu Huang, Ying Wang, Ji-Ye Aa, Fang Zhou
Apatinib, a small-molecule inhibitor of VEGFR-2, has attracted much attention due to its encouraging anticancer activity in third-line clinical treatment for many malignancies, including non-small cell lung cancer (NSCLC). Its usage in second-line therapy with chemotherapeutic drugs is still under exploration. In this study we investigated the antitumor effect of apatinib combined with docetaxel against NSCLC and its cellular pharmacokinetic basis. A549 xenograft nude mice were treated with apatinib (100 mg/kg every day for 20 days) combined with docetaxel (8 mg/kg, ip, every four days for 5 times)...
May 17, 2018: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/29767464/platinum-resistant-recurrent-ovarian-cancer-with-long-survival-on-bevacizumab-and-gemcitabine
#5
Shinichi Komiyama, Tsuyoki Kugimiya, Chiaki Takeya, Rena Takahashi, Kaneyuki Kubushiro
Platinum-resistant recurrent ovarian cancer has a poor prognosis, but combined therapy with bevacizumab and anticancer agents may be useful. We report a patient with long-term disease control by the combination of bevacizumab and gemcitabine (BEV + GEM). The patient was a 77-year-old woman with high-grade Stage IIIC serous ovarian carcinoma. In 2012, a complete response (CR) was obtained by neoadjuvant and adjuvant chemotherapy using paclitaxel plus carboplatin and tumor debulking surgery. After recurrence in 2013, CR was achieved again with gemcitabine plus carboplatin...
May 16, 2018: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/29764596/-a-case-report-of-advanced-lung-adenocarcinoma-harboring-kras-mutation-treated-with-anlotinib
#6
Yudong Su, Zhaoting Meng, Xiaoyan Xu, XinYue Wang, Ran Zuo, Yunxia Hou, Kai Li, Peng Chen
In recent years, the number of advanced non-small cell lung cancer (NSCLC) patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to targeted therapy epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) or chemotherapy. The clinical treatment effect is also not satisfactory. Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit...
May 20, 2018: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29755765/travel-distance-and-use-of-salvage-palliative-chemotherapy-in-patients-with-metastatic-colorectal-cancer
#7
Shahid Ahmed, Mahjabeen Iqbal, Duc Le, Nayyer Iqbal, Punam Pahwa
Background: Salvage palliative chemotherapy in metastatic colorectal cancer has been associated with significant improvement in survival. However, not all patients receive all available therapies. Travel burden can affect patient access and use of future therapy. The present study aims to determine relationship between travel distance (TD) and salvage palliative chemotherapy in patients with metastatic colorectal cancer. Method: A patient cohort diagnosed with metastatic colorectal cancer during 2006-2010 in the province of Saskatchewan, Canada was studied...
April 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29753637/safety-and-efficacy-of-cabozantinib-in-metastatic-renal-cell-carcinoma-real-world-data-from-an-italian-managed-access-program
#8
Giuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, Enrico Cortesi, Giuseppe Fornarini, Gaetano Facchini, Giacomo Cartenì, Roberto Sabbatini, Gabriella Del Bene, Luca Galli, Claudia Caserta, Andrea Giovanni Multari, Marco Bregni, Francesco Massari, Sebastiano Buti, Ugo De Giorgi, Fable Zustovich, Michele Milella, Fabio Calabrò, Maria Laura Mancini, Giampaolo Tortora, Claudio Vernieri, Daniele Santini, Mariella Sorarù, Riccardo Ricotta, Cristina Masini, Marcello Tucci, Stefano Luzi Fedeli, Cinzia Ortega, Antonella Mecozzi, Raffaele Ratta, Cora N Sternberg, Elena Verzoni
BACKGROUND: The randomized phase 3 METEOR study confirmed a survival benefit of cabozantinib over everolimus in patients with metastatic renal-cell carcinoma (mRCC) with disease that progressed after treatment with at least one previous antiangiogenic inhibitor. The aim of this analysis was to evaluate the safety and activity of cabozantinib in an unselected population. METHODS: Data were collected across 24 Italian centers. Cabozantinib therapy was initiated at physician request between September and December 2016...
April 19, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29746857/women-undergoing-third-line-overactive-bladder-treatment-demonstrate-elevated-thermal-temporal-summation
#9
W Stuart Reynolds, Casey Kowalik, Joshua Cohn, Melissa Kaufman, Alan Wein, Roger Dmochowski, Stephen Bruehl
PURPOSE: To determine if women with overactive bladder (OAB) requiring 3rd line therapy demonstrate greater central sensitization, indexed by temporal summation to heat pain stimuli, than those with OAB. MATERIALS AND METHODS: We recruited 39 adult women with OAB from the Urology clinic who were planning to undergo interventional therapy for medication refractory OAB with either onabotulinumtoxinA bladder injection or sacral neuromodulation and 55 women with OAB, either newly seen in our Urology clinic or responding to advertisements for study participation...
May 7, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29740957/egfr-exon-20-insertion-mutation-in-advanced-thymic-squamous-cell-carcinoma-response-to-apatinib-and-clinical-outcomes
#10
Su Yudong, Meng Zhaoting, Wang Xinyue, Lin Li, Xu Xiaoyan, Zuo Ran, Chen Jinliang, Chen Peng
Thymic carcinoma (TC) is a rare malignant tumor of the mediastinum with occult onset, rapid development, and poor prognosis. Surgery is the main treatment for early TC, but the majority of patients are diagnosed at Masaoka-Koga stage III or IV with local invasion or distant metastasis. Platinum and anthracyclines are currently considered key components of first-line chemotherapy for advanced TC; however, there are no standard treatment plans for patients who are refractory to first-line and further chemotherapy...
May 8, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29739622/phase-ii-study-of-single-agent-cabozantinib-in-patients-with-recurrent-clear-cell-ovarian-primary-peritoneal-or-fallopian-tube-cancer-nrg-gy001
#11
Panagiotis A Konstantinopoulos, William E Brady, John Farley, Amy Armstrong, Denise S Uyar, David M Gershenson
OBJECTIVE: To evaluate the efficacy and tolerability of cabozantinib in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer. METHODS: Patients with recurrent ovarian, fallopian or primary peritoneal tumors with at least 50% clear cell histomorphology, measurable disease, one or two prior regimens and ECOG performance status 0-2 received cabozantinib 60 mg orally once daily continuously, in 4-week cycles until disease progression or unacceptable toxicity...
May 5, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29737410/executive-summary-of-the-clinical-guidelines-of-pharmacotherapy-for-neuropathic-pain-second-edition-by-the-japanese-society-of-pain-clinicians
#12
REVIEW
Masahiko Sumitani, Tetsuya Sakai, Yoichi Matsuda, Hiroaki Abe, Shigeki Yamaguchi, Toyoshi Hosokawa, Sei Fukui
Neuropathic pain has a substantial effect on quality of life (QOL). The Japanese Society of Pain Clinicians (JSPC) has developed clinical guidelines of pharmacotherapy for neuropathic pain. These guidelines offer clarity on recommendations based on both the most recent scientific evidence and expert opinions. Understanding the concept, disease entity, and burden of neuropathic pain, as well as its screening and diagnosis are important steps before starting pharmacotherapy. As well as other guidelines, the guidelines propose several lines of pharmacotherapies in a step-wise manner...
May 8, 2018: Journal of Anesthesia
https://www.readbyqxmd.com/read/29732725/time-trends-and-geographical-variation-in-prescribing-of-drugs-for-diabetes-in-england-1998-2017
#13
Helen J Curtis, John M Dennis, Beverley M Shields, Alex J Walker, Seb Bacon, Andrew T Hattersley, Angus G Jones, Ben Goldacre
AIMS: UK guidelines for type II diabetes leave the choice of glucose lowering therapies after metformin largely to prescribers. They vary greatly in cost, and comparative effectiveness data is lacking. We set out to measure the variation in prescribing of these second-line non-insulin diabetes drugs. MATERIALS AND METHODS: We evaluated time trends 1998-2016, using England's publicly available prescribing datasets, and stratified by the order prescribed to patients using the Clinical Practice Research Datalink (CPRD)...
May 7, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29731400/treatment-of-infantile-spasms-by-pediatric-neurologists-in-japan
#14
Shin-Ichiro Hamano, Toshisaburo Nagai, Ryuki Matsuura, Yuko Hirata, Satoru Ikemoto, Atsuko Oba, Erika Hiwatari
OBJECTIVE: To clarify changes in clinical practice for infantile spasms, including West syndrome, in Japan over the past two decades. METHODS: We investigated common treatment strategies for infantile spasms among 157 pediatric neurologists from a designated training facility for pediatric neurology and/or a designated training facility for epilepsy in Japan. A questionnaire was used to investigate use of adrenocorticotropic hormone (ACTH) therapy including daily dose, treatment duration, and tapering off period, and preferred first to fifth-line treatment choices...
May 3, 2018: Brain & Development
https://www.readbyqxmd.com/read/29730461/evolution-of-checkpoint-inhibitors-for-the-treatment-of-metastatic-gastric-cancers-current-status-and-future-perspectives
#15
REVIEW
Julien Taieb, Markus Moehler, Narikazu Boku, Jaffer A Ajani, Eduardo Yañez Ruiz, Min-Hee Ryu, Silke Guenther, Vikram Chand, Yung-Jue Bang
BACKGROUND: Standard treatment options for patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) are associated with limited efficacy and some toxicity. Recently, immunotherapy with antibodies that inhibit the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) interaction has emerged as a new treatment option. This manuscript reviews early-phase and late-phase trials of immunotherapy in advanced GC/GEJC. METHODS: Searches for studies of immunotherapy in GC/GEJC were performed using PubMed, ClinicalTrials...
April 22, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29720233/real-world-evidence-analysis-of-palbociclib-prescribing-patterns-for-patients-with-advanced-metastatic-breast-cancer-treated-in-community-oncology-practice-in-the-usa-one-year-post-approval
#16
J K Kish, M A Ward, D Garofalo, H V Ahmed, L McRoy, J Laney, G Zanotti, J Braverman, H Yu, B A Feinberg
BACKGROUND: Rapidly evolving understanding of cancer biology has presented novel opportunities to translate that understanding into clinically relevant therapy. Palbociclib, a novel, first-in-class cyclin-dependent kinase (CDK) 4/6 inhibitor was approved in the USA in February 2015 for the treatment of advanced/metastatic breast cancer. We examined real-world evidence in the first year post approval to understand the clinical and demographic characteristics of patients treated with palbociclib in community oncology practices and the dosing, treatment, and complete blood count (CBC) monitoring patterns...
May 2, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29719129/adult-acute-rhinosinusitis-guidelines-worldwide-similarities-and-disparities
#17
Ofer Gluck, Tal Marom, Shay Shemesh, Sharon Ovnat Tamir
BACKGROUND: Acute rhinosinusitis (ARS) is a common respiratory infection that poses a major public healthcare burden with respect to antibiotic consumption and related morbidity. Position statements and national ARS guidelines have been published worldwide, aiming to define diagnostic criteria and outline treatment options. Our objective was to analyze the similarities and disparities between such guidelines. METHODS: We conducted an electronic database search for ARS guidelines using relevant keywords between January 1, 1989, through December 31, 2017...
May 2, 2018: International Forum of Allergy & Rhinology
https://www.readbyqxmd.com/read/29714652/real-world-evidence-in-metastatic-renal-cell-carcinoma
#18
Jeffrey Graham, Daniel Yc Heng
Real-world evidence has played an important role in expanding our knowledge on the treatment and prognostication of advanced renal cell carcinoma. This type of data has been particularly helpful in providing a better understanding of groups that are traditionally excluded from randomized controlled trials. The International mRCC Database Consortium (IMDC) represents the largest collection of real-world data on patients with advanced kidney cancer treated with targeted therapies. The IMDC prognostic model has been used to stratify patients in contemporary clinical trials and to provide risk-directed treatment selection in everyday clinical practice...
March 1, 2018: Tumori
https://www.readbyqxmd.com/read/29713867/treatment-of-adult-idiopathic-inflammatory-myopathies-with-conventional-immunosuppressive-drugs-results-of-a-retrospective-study
#19
G Keyßer, S Zierz, M Kornhuber
OBJECTIVES: To gain information about the efficacy of immunosuppressive drugs as first-, second-, and third-line treatment of idiopathic inflammatory myopathies (IIM). METHODS: 112 treatment cycles of 63 patients with dermatomyositis (n = 23), polymyositis (n = 33), overlap syndromes (n = 4), and undifferentiated connective tissue diseases (n = 3) were analyzed by retrospective chart analysis. Data regarding muscle strength, muscle enzymes, treatment duration, and treatment discontinuation were collected...
April 30, 2018: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/29713649/treatment-discontinuation-and-clinical-events-in-type-2-diabetes-patients-treated-with-dipeptidyl-peptidase-4-inhibitors-or-nph-insulin-as-third-line-therapy
#20
Cristiano S Moura, Zale B Rosenberg, Michal Abrahamowicz, Sasha Bernatsky, Hassan Behlouli, Louise Pilote
Objective: To compare dipeptidyl peptidase-4 (DPP-4) inhibitors with neutral protamine Hagedorn (NPH) insulin, in terms of effectiveness and safety for the management of patients with type 2 diabetes mellitus (DM2) not controlled on metformin and sulfonylureas. Methods: A retrospective cohort study of individuals with DM2 newly dispensed with either DPP-4 inhibitors or NPH as third-line therapy, after metformin and sulfonylurea. Treatment discontinuation, macrovascular outcomes, and hypoglycemia were compared using multivariable Cox regression models, adjusted for sex, age, year of cohort entry, place of residence, hypertension, past history of hypoglycemia, diabetic ketoacidosis, comorbidities, and number of visits to emergency departments, outpatient physician, and hospitalizations...
2018: Journal of Diabetes Research
keyword
keyword
114246
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"